title: Unmasking glucose metabolism alterations in stable renal transplant recipients: a multicenter study.
abstract: OBJECTIVE
  Emerging information indicates that glucose metabolism alterations are common after renal transplantation and are associated with carotid atheromatosis. The aims of this study were to investigate the prevalence of different glucose metabolism alterations in stable recipients as well as the factors related to the condition.
  
  
  METHODS
  A multicenter, cross-sectional study was conducted of 374 renal transplant recipients without pre- or posttransplantation diabetes. A standard 75-g oral glucose tolerance test was performed.
  
  
  RESULTS
  Glucose metabolism alterations were present in 119 (31.8%) recipients: 92 (24.6%) with an abnormal oral glucose tolerance test and 27 (7.2%) with isolated impaired fasting glucose. The most common disorder was impaired glucose tolerance (17.9%), and an abnormal oral glucose tolerance test was observed for 21.5% of recipients with a normal fasting glucose. By multivariate analysis, age, prednisone dosage, triglyceride/high-density lipoprotein cholesterol ratio, and beta blocker use were shown to be factors related to glucose metabolism alterations. Remarkably, triglyceride levels, triglyceride/high-density lipoprotein cholesterol ratio, and the proportion of recipients with impaired fasting glucose were already higher throughout the first posttransplantation year in recipients with a current glucose metabolism alteration as compared with those without the condition.
  
  
  CONCLUSIONS
  Glucose metabolism alterations are common in stable renal transplant recipients, and an oral glucose tolerance test is required for its detection. They are associated with a worse metabolic profile, which is already present during the first posttransplantation year. These findings may help planning strategies for early detection and intervention.
authors.affiliation: Nephrology Section and Research Unit, Hospital Universitario de Canarias, University of La Laguna (Tenerife), Spain.
authors.forename: Patricia
authors.initials: P
authors.lastname: Delgado
authors.forename: Juan Manuel
authors.initials: JM
authors.lastname: Diaz
authors.forename: Irene
authors.initials: I
authors.lastname: Silva
authors.forename: José M
authors.initials: JM
authors.lastname: Osorio
authors.forename: Antonio
authors.initials: A
authors.lastname: Osuna
authors.forename: Beatriz
authors.initials: B
authors.lastname: Bayés
authors.forename: Ricardo
authors.initials: R
authors.lastname: Lauzurica
authors.forename: Edgar
authors.initials: E
authors.lastname: Arellano
authors.forename: Jose Maria
authors.initials: JM
authors.lastname: Campistol
authors.forename: Rosa
authors.initials: R
authors.lastname: Dominguez
authors.forename: Carlos
authors.initials: C
authors.lastname: Gómez-Alamillo
authors.forename: Meritxell
authors.initials: M
authors.lastname: Ibernon
authors.forename: Francisco
authors.initials: F
authors.lastname: Moreso
authors.forename: Rocio
authors.initials: R
authors.lastname: Benitez
authors.forename: Ildefonso
authors.initials: I
authors.lastname: Lampreave
authors.forename: Esteban
authors.initials: E
authors.lastname: Porrini
authors.forename: Armando
authors.initials: A
authors.lastname: Torres
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000009:adverse effects; D000328:Adult; D000367:Age Factors; D001786:Blood Glucose / Q000378:metabolism*; D003430:Cross-Sectional Studies; D003920:Diabetes Mellitus / Q000097:blood / Q000453:epidemiology / Q000209:etiology*; D005215:Fasting / Q000097:blood; D005260:Female; D018149:Glucose Intolerance / Q000097:blood / Q000453:epidemiology / Q000209:etiology*; D005951:Glucose Tolerance Test; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects; D016030:Kidney Transplantation / Q000009:adverse effects* / Q000706:statistics & numerical data; D008055:Lipids / Q000097:blood; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio; D011241:Prednisone / Q000009:adverse effects; D015995:Prevalence; D018570:Risk Assessment; D012307:Risk Factors; D013030:Spain / Q000453:epidemiology; D013997:Time Factors
chemical_list: D000319:Adrenergic beta-Antagonists; D001786:Blood Glucose; D007166:Immunosuppressive Agents; D008055:Lipids; D011241:Prednisone